

Kirjallisuusviitteet: X-ALD ja AMN

Bezman L, Moser AB, Raymond GV, ym: Adrenoleukodystrophy: incidence, new mutation rate, and results of extended family screening. *Ann Neurol* 2001 April;49(4):512-7.

Dunne E, Hyman NM, Huson SM, ym: A novel point mutation in X-linked adrenoleukodystrophy presenting as a spinocerebellar degeneration. *Ann Neurol* 1999;45:652-5.

Edwin D, Speedie LJ, Kohler W, ym: Cognitive and brain magnetic resonance imaging findings in adrenomyeloneuropathy. *Ann Neurol* 1996 Oct;40(4):675-8.

Ferri R, Chance PF: Lorenzo's oil: advances in the treatment of neurometabolic disorders. *Arch Neurol*. 2005 Jul;62(7):1045-6.

Kemp S, Pujol A, Waterham HR, ym: ABCD1 mutations and the X-linked adrenoleukodystrophy mutation database: role in diagnosis and clinical correlations. *Hum Mutat* 2001 Dec;18(6):499-515.

Kemp S, Wei H-M, Lu J-F, ym: Gene redundancy and pharmacological gene therapy: Implications for X-linked adrenoleukodystrophy. *Nat Med* 1998;4:1261-8.

Kumar AJ, Kohler W, Kruse B, ym: MR findings in adult-onset adrenoleukodystrophy. *AJNR Am J Neuroradiol* 1995 Jun-Jul;16(6):1227-37.

Moser Hugo W: Adrenoleukodystrophy: phenotype, genetics, pathogenesis and therapy. *Brain* 1997;120:1485-1508.

Moser HW, Mahmood A. New insights about hematopoietic stem cell transplantation in adrenoleukodystrophy. *Arch Neurol*. 2007 May;64(5):631-2.

Moser HW, Raymond GV, Lu SE, ym: Follow-up of 89 asymptomatic patients with adrenoleukodystrophy treated with Lorenzo's oil. *Arch Neurol*. 2005 Jul;62(7):1073-80.

Netik A, Forss-Petter S, Holzinger A, ym: Adrenoleukodystrophy-related protein can compensate functionally for adrenoleukodystrophy protein deficiency (X-ALD): implications for therapy. *Hum Mol Genet* 1999;8(5):907-13.

Poser C, Goutières F, Carpentier M-A, ym: Schilder's myelinoclastic diffuse sclerosis. *Pediatrics* 1986, 77(1): 107-12.

Restuccia D, Di Lazzaro V, Valeriani M, ym: Neurophysiologic follow-up of long-term dietary treatment in adult-onset adrenoleukodystrophy. *Neurology* 1999 Mar 10;52(4):810-6.

Schönberger S, Roerig P, Schneider DT, ym: Genotype and protein expression after bone marrow transplantation for adrenoleukodystrophy. *Arch Neurol*. 2007 May;64(5):651-7.

Shapiro E, Krivit W, Lockman L, ym: Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy. *Lancet* 2000 Aug 26;356(9231):713-8.

Singh I, Khan M, Key L: Lovastatin for X-linked adrenoleukodystrophy. *N Engl J Med* 1998 Sep 3;339:702-3.

Singh I, Pahan K, Khan M: Lovastatin and sodium phenylacetate normalize the levels of very long chain fatty acids in skin fibroblasts of X-adrenoleukodystrophy. *FEBS Lett* 1998 Apr 24;426(3):342-6.

Vainionpää L, Salo M, Jolma T, ym: X-adrenoleukodystrofia - selitys poikien kouluongelmille, miesten kävelyvaikeuksille ja Addisonin taudille. *Duodecim* 1997;113:1883-9.

Van Geel BM, Bezman L, Loes DJ, ym: Evolution of phenotypes in adult male patients with X-linked adrenoleukodystrophy. *Ann Neurol* 2001;49:186-94.

Van Geel BM, Assies J, Haverkort EB, ym: Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with "Lorenzo's oil". *J Neurol Neurosurg Psychiatry* 1999;67:290-9.